- Home
- STAI vs PRPO Comparison
STAI vs PRPO Comparison
Compare STAI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- PRPO
- Stock Information
- Founded
- STAI 2011
- PRPO N/A
- Country
- STAI United States
- PRPO United States
- Employees
- STAI N/A
- PRPO N/A
- Industry
- STAI
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- STAI
- PRPO Industrials
- Exchange
- STAI Nasdaq
- PRPO Nasdaq
- Market Cap
- STAI 22.6M
- PRPO 22.0M
- IPO Year
- STAI N/A
- PRPO N/A
- Fundamental
- Price
- STAI $0.46
- PRPO $14.26
- Analyst Decision
- STAI
- PRPO
- Analyst Count
- STAI 0
- PRPO 0
- Target Price
- STAI N/A
- PRPO N/A
- AVG Volume (30 Days)
- STAI 24.9M
- PRPO 8.2K
- Earning Date
- STAI 01-01-0001
- PRPO 08-13-2025
- Dividend Yield
- STAI N/A
- PRPO N/A
- EPS Growth
- STAI N/A
- PRPO N/A
- EPS
- STAI N/A
- PRPO N/A
- Revenue
- STAI $907,637.00
- PRPO $21,242,000.00
- Revenue This Year
- STAI N/A
- PRPO N/A
- Revenue Next Year
- STAI N/A
- PRPO N/A
- P/E Ratio
- STAI N/A
- PRPO N/A
- Revenue Growth
- STAI N/A
- PRPO 27.05
- 52 Week Low
- STAI $0.42
- PRPO $3.90
- 52 Week High
- STAI $9.07
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- PRPO 51.60
- Support Level
- STAI N/A
- PRPO $13.80
- Resistance Level
- STAI N/A
- PRPO $15.41
- Average True Range (ATR)
- STAI 0.00
- PRPO 0.35
- MACD
- STAI 0.00
- PRPO -0.08
- Stochastic Oscillator
- STAI 0.00
- PRPO 28.57
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.